Novonesis: Still Too Expensive
Novonesis is a strong business with stable margins and high ROIC, but recent growth rates have declined. See why NVZMF stock ...
worldbiomarketinsights2d
The Danish bio-producer that made it in China
ContentsThe global face of Danish biotechWhy China?Meeting China’s needsFirst mover advantageTodayAs Western investments back ...